Brain Behavior and Immunity Integrative最新文献

{"title":"Neuro-immune-cancer interactions: Mechanisms and therapeutic implications for tumor modulation","authors":"Jianzhuang Wu,&nbsp;Xinyi Lu,&nbsp;Chao Yan","doi":"10.1016/j.bbii.2025.100119","DOIUrl":"10.1016/j.bbii.2025.100119","url":null,"abstract":"<div><div>The interplay between neurons, the immune system, and cancer is a critical area of research with significant therapeutic potential. Neurons regulate immune responses and directly influence tumor progression through neurotransmitters, neurotrophic factors, and synaptic interactions with tumor cells. The peripheral nervous system modulates immune cell activity and inflammation, while the central nervous system coordinates systemic immune responses, influencing tumor growth and metastasis. This neuro-immune-tumor crosstalk is particularly important in peripheral tumors, where local neuroimmune regulation plays a pivotal role. Emerging neuromodulatory therapies, such as Vagus Nerve Stimulation (VNS), offer promising strategies to modulate these interactions. Despite these advances, challenges remain in optimizing neuromodulation and understanding the molecular mechanisms underlying these complex interactions. This perspective highlights the potential for targeting neuro-immune-cancer pathways, with a focus on personalized and precise therapies to address tumor heterogeneity and improve treatment outcomes.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100119"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The rapid onset of response to depression treatment by Yueju pill: From discovery of a novel treatment target to clinical perspective","authors":"Ruiyi Liu ,&nbsp;Zhangjie Wu ,&nbsp;Ying Yin ,&nbsp;Shan Xing ,&nbsp;Changyu Wu ,&nbsp;Yan Sun ,&nbsp;Hailou Zhang ,&nbsp;Gang Chen","doi":"10.1016/j.bbii.2025.100121","DOIUrl":"10.1016/j.bbii.2025.100121","url":null,"abstract":"<div><div>Depression, marked by persistent low mood and anhedonia, poses significant global health challenges, whereas mainstream antidepressants like SSRIs often have delayed onset and limited efficacy. Yueju Pill, a traditional Chinese herbal medicine formulated 800 years ago to treat “stagnation syndrome”, which overlaps with depression. Yueju pill has been shown to have the rapid onset and sustained antidepressant potential since 2013. It has been revealed to have similarities to the prototype rapid antidepressant ketamine in neuroplasticity mechanisms, including instant stimulation of protein synthesis signaling in the hippocampus and prefrontal cortex, subsequently enhancing expressions of BDNF and synaptic proteins. More recently, some targets and compound substrates that were not known before have been revealed from Yueju pill, and some clinical evidence has been provided. This review will focus on the advances in the discovery of a novel target, the neuropeptide PACAP in the hippocampus for the onset of depression treatment, the study paradigm employed to identify the synergism of the composing compounds in Yueju pill targeting PACAP, the mechanisms of neuroinflammation and gut-brain axis, and clinical trials showing fast alleviation of depression symptoms by adjunct or monotherapy with Yueju pill, in relationship to the improvement in serum BDNF levels. The perspective for a broader use of Yueju pill as a therapeutic avenue for depression and further mechanistic and clinical research directions is also provided.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100121"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The modulation of post-translational modification of proteins by physical exercise to improve brain functions via affecting metabolic homeostasis","authors":"Li Zhang","doi":"10.1016/j.bbii.2025.100120","DOIUrl":"10.1016/j.bbii.2025.100120","url":null,"abstract":"<div><div>Exercise training effectively prevents mental or cognitive deficits, as supported by both animal studies and clinical trials. Our group has been focused on the peripheral derived molecules under endurance exercise scheme and is investigating the possible function of these factors in modulating brain functions. In particular, our recent works have shown the involvement of specific exercise metabolites in reshaping the posttranslational modification of synaptic proteins, to enhance the neural networking for counteracting mental disorders. In this article, I will briefly elaborate the recent progress regarding the linkage among exercise training, circulating metabolites and synaptic functions, in order to provide some previously unrecognized pathways for the brain health effect of exercise. In addition, the possibly future directions of the study for exercise-mediated metabolic homeostasis and brain function will be discussed.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143786283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic inflammation linking atherosclerosis to cognitive impairment: Multi-target mechanisms and therapeutic advances in chinese herbal medicine","authors":"Rumin Huang ,&nbsp;Xiangrui Zhang ,&nbsp;Meiling Ni ,&nbsp;Xinyi Chen ,&nbsp;Yanqing Wang ,&nbsp;Wenwen Chang ,&nbsp;Yan Sun ,&nbsp;Haoxin Wu","doi":"10.1016/j.bbii.2025.100122","DOIUrl":"10.1016/j.bbii.2025.100122","url":null,"abstract":"<div><div>The chronic inflammatory state associated with vascular aging plays a critical role in the pathogenesis of age-related diseases, including occurrence and progression of atherosclerosis (AS) and cognitive impairment (CI). The detrimental impacts of inflammation are multifaceted. On the one hand, inflammation impairs the function of vascular endothelial cells (EC) and contributes to vascular remodeling. On the other hand, it triggers a cascade of events resulting in cerebral small vessel disease (CSVD), which disrupts the blood-brain barrier (BBB), induces neuroinflammation and ultimately impairs cognitive function. Consequently, these processes establish a strong pathological link between atherosclerosis (AS) and cognitive impairment (CI). Chinese Herbal Medicine(CHM) posits that AS and CI share common pathological factors and similar pathogeneses. According to CHM theory, the aging process is associated with a gradual deficiency of healthy qi, which subsequently results in spleen qi deficiency and impaired transportation functions. This dysfunction leads to the accumulation of water-dampness, which can further transform into pathogenic fire, thereby causing damage to the veins and channels. Clinically, such pathological changes may manifest as cardiac pain, dementia, and other symptoms. The treatment of AS in CHM follows principles such as clearing heat, removing toxins, as well as eliminating phlegm and resolving blood stasis. It is notable that numerous studies have demonstrated that Chinese herbs exhibit distinctive therapeutic potential in modulating the progression of CI associated with AS. These herbs have been observed to target multiple pathways intricately involved in AS-related inflammatory processes and cognitive impairment, offering a comprehensive therapeutic approach. In light of the above, this review aims to provide an overview of the evidence supporting the association between AS and CI. It will explore the pathological mechanisms and processes by which AS contributes to the development of CI, and summarize the mechanism of action of Chinese herbs in the treatment of AS-related CI. The findings aim to inform future therapeutic strategies for cognitive disorders and guide research directions in this field.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100122"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143807016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of Jin's three-needle therapy for Tardive dyskinesia","authors":"Yaodong Xian ,&nbsp;Jinxiu Hu ,&nbsp;Xueying Yang ,&nbsp;Yan Ding ,&nbsp;Wei Li ,&nbsp;Lanying Liu","doi":"10.1016/j.bbii.2025.100118","DOIUrl":"10.1016/j.bbii.2025.100118","url":null,"abstract":"<div><div>The objective of this case study was to investigate the effectiveness of Jin’s three-needle therapy in treating tardive dyskinesia (TD). TD is a movement disorder resulting from long-term use of antipsychotics. It is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts.The participant in this study was a 69-year-old male who had been diagnosed with schizophrenia at the age of 45 years and TD at the age of 64 years. His chief complaints included “mouth pumping,” sucking, and a rubbing motion of his fingers. After using Jin’s three-needle therapy five times a week for 20 treatments, the patient reported an 80 % reduction in all symptoms. The patient’s Abnormal Involuntary Movement Scale (AIMS) score decreased from 19 to 10, and the Tardive Dyskinesia Rating Scale (TDRS) score decreased from 67 to 55. In this case, the results indicated that Jin’s three-needle therapy was able to decrease the symptoms of TD. Further investigation is needed to support this argument. The treatment for TD is mainly based on western medicine. However, currently Western medicine cannot completely control symptoms, and there is a high possibility of drug side effects. It was challenging to find literature on acupuncture for treating TD, particularly in English. Jin’s three-needle therapy, a characteristic acupuncture therapy in China, is widely used in clinical practice.This article analyzes the treatment process of a case of treating TD with “Jin’s three-needle therapy.” It is hoped that it can provide reference for the treatment of such diseases and feasibility for the next large-scale related research.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Chinese patent medicine Wuling capsule combined with antidepressant drugs in the treatment of major depressive disorder: A systematic review with meta-analysis","authors":"Wangtao Li ,&nbsp;Yang Shao ,&nbsp;Mengjuan Xing ,&nbsp;Qiong Xiang ,&nbsp;Liyuan Guo ,&nbsp;Yiying Hu ,&nbsp;Wei Li ,&nbsp;Lanying Liu","doi":"10.1016/j.bbii.2025.100116","DOIUrl":"10.1016/j.bbii.2025.100116","url":null,"abstract":"<div><h3>Background</h3><div>Major depressive disorder is a public health problem covering the world. Medical therapy is one of the main treatment for Major depressive disorder. However, antidepressants often have delayed efficacy and many side effects, which seriously affect the quality of life of patients. To systematically evaluate the efficacy and safety of Chinese patent medicine Wuling capsule combined with antidepressant drug in the treatment of patients with Major depressive disorder. Wuling capsule is a traditional Chinese medicine in China consisting of Wuling mycelia of Xylaria nigripes Sacc (a rare type of fungus).</div></div><div><h3>Methods</h3><div>Relevant documents published before December 1st, 2023 were retrieved from China national knowledge infrastructure, WANFANG DATA, SinoMed, Vip Journal Integration Platform, Chinese Bio Medical Literature Database, Web of Science, Pubmed, Embase, PsycINFO, International Clinical Trials Registry Platform, Scopus, CINAHL, ProQuest, Wiley Online Library and Clinicaltrials.gov. Randomized controlled trials that meet the inclusion criteria were selected. Their qualities were evaluated and classified. The meta-analysis was performed using RevMan 5.4, and heterogeneity test and publication bias evaluation were performed.</div></div><div><h3>Results</h3><div>This review includes 2148 patients from 24 studies. In this study, the intervention group chose Wuling capsule combined with Antidepressant, and the control group used antidepressants alone. The results show that compared with using antidepressant drug alone, using Wuling capsule combined with antidepressant drug displays statistical significance in reduction of patients’ Hamilton Depression Scale score [mean difference= -3.08, 95 %CI (-3.58,-2.57), P &lt; 0.001], Treatment Emergent Symptom Scale score [mean difference= -3.00, 95 %CI (-4.24, −1.75), P &lt; 0.001], and the effective rate [risk ratio= 1.18, 95 %CI (1.13, 1.23), P &lt; 0.001].</div></div><div><h3>Conclusions</h3><div>Compared with antidepressants alone, the Wuling capsule has an advantage in improving the Hamilton Depression score of patients with major depressive disorder. Through this study, we believe that the Wuling capsule can be used as a safe and effective adjunctive drug for the treatment of Chinese patients with major depressive disorder. However, the quality of the evidence still needs to be further improved, and more high-quality clinical trials from different regions are needed to enhance the credibility of the evidence.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential benefits of kefir and its compounds on Alzheimer's disease: A systematic review","authors":"Yuri Castelo Branco Tanure ,&nbsp;Ana Clara Morais Mafra ,&nbsp;Bruna Luiza Motta Guimarães ,&nbsp;Rafael Coelho Magalhães ,&nbsp;Catherine Fagundez ,&nbsp;Israel Júnior Borges do Nascimento ,&nbsp;Julio Cesar Moreira Brito","doi":"10.1016/j.bbii.2025.100115","DOIUrl":"10.1016/j.bbii.2025.100115","url":null,"abstract":"<div><div>Alzheimer's disease, characterized by the progressive loss of cognitive functions of the brain, is still an incurable pathology. Current treatments primarily aim to alleviate symptoms, acting mainly on behavioral changes, having a modest impact in the disease course. Recently, potential role of probiotics in managing Alzheimer's has been explored. Kefir, a fermented food teeming with live microorganisms, is thought to influence the gut microbiota, potentially reducing inflammation and the accumulation of toxic proteins in the brain. Additionally, kefir contains bioactive compounds, such as B vitamins, choline, and folic acid, which are essential for neuronal health and cognitive function. Thus, kefir could emerge as a promising complementary treatment for Alzheimer's disease. This systematic review, conducted in January 2024, examined the effects of kefir in both in vivo animal models and human patients with neurodegenerative conditions. The review was based on studies retrieved from BVS, Embase, PubMed/MEDLINE, Scopus, and Web of Science databases. Seven studies were included, involving invertebrates, murine models, and human participants. In animal models, the primary outcomes were antioxidant effects, reduced beta-amyloid deposition, and attenuation of vascular damage and neurodegeneration. In human studies, kefir supplementation resulted in decreased levels of inflammatory cytokines, reactive oxygen species (ROS), and oxidative proteins, and was associated with improvements in memory. Given its potential benefits, kefir could serve as a valuable adjunct to conventional treatments for Alzheimer's disease, warranting further investigation in clinical settings.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining network pharmacology and bioinformatics approaches to explore the molecular mechanism of Erdong Nourishing Heart oral solution in the treatment of anxiety disorders","authors":"Yihan Guo ,&nbsp;Dongdong Shi ,&nbsp;Qing Zhao ,&nbsp;Weidi Wang ,&nbsp;Lanying Liu ,&nbsp;Zhen Wang","doi":"10.1016/j.bbii.2025.100117","DOIUrl":"10.1016/j.bbii.2025.100117","url":null,"abstract":"<div><h3>Background</h3><div>Erdong Nourishing Heart oral solution (EDYX) is a traditional in-hospital formula used for the clinical treatment of anxiety disorders at the Shanghai Mental Health Center; however, its active medicinal components and mechanisms of action remain unexplored.</div></div><div><h3>Methods</h3><div>Active compounds of EDYX and their corresponding targets were identified using the TCMSP, Symmap, and Herb databases. Data intersecting the targets of EDYX and anxiety disorders were obtained from the GeneCards, OMIM, and CTD databases.We take the intersecting targets of EDYX and anxiety disorders to construct a PPI network and a ingredient-disease-target network.Network parameters were analyzed systematically using Cytoscape software, deriving the core targets and key components of EDYX's mechanism.Molecular docking methods assessed and verified interactions between core targets and key components, while the reliability of drug targets was confirmed using the GEO dataset.</div></div><div><h3>Findings</h3><div>A total of 59 active compounds and 3574 corresponding pharmacotherapeutic targets were identified for EDYX, while 6894 targets relevant to anxiety disorders were also screened. Systematic analysis of 1587 potential common targets between EDYX and anxiety disorders revealed core components of EDYX, including polyphenolic compounds such as quercetin, stigmasterol, and γ-sitosterol, and core targets such as TP53,SRC,AKT1,CXCL8 and CXCR4. Pathway enrichment analysis suggested that EDYX potentially inhibits neuroinflammation, enhances cell proliferation and metabolism, and alleviates anxiety by modulating signaling pathways including JUN-STAT, MAPK-NK-κB, PI3K-AKT-mTOR, and neuroactive ligand-receptor interactions.The results of molecular docking showed that the docking scores of JUN and EP300 target proteins with the key compounds were significantly lower than the other proteins, which may be the potential binding targets of EDYX for the treatment of Anxiety. The results of GEO database validation indicated that MMP8 and FOSB may be potential impact genes for EDYX treatment of Anxiety.</div></div><div><h3>Conclusions</h3><div>EDYX is a Chinese medicine compound preparation with multi-component, multi-target, and multi-pathway antidepressant efficacy, which is expected to be a powerful choice for the future adjuvant treatment of Anxiety.Further molecular experiments are required to verify the molecular mechanism of EDYX and its active ingredients, providing a theoretical basis for clinical application.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xathine unveiled: Bridging CD4+ T cell and stress-induced disorders through purine metabolism","authors":"Li Zhang ,&nbsp;Jia-xin Dong ,&nbsp;Yi-yuan Li ,&nbsp;Jin Jin","doi":"10.1016/j.bbii.2025.100113","DOIUrl":"10.1016/j.bbii.2025.100113","url":null,"abstract":"<div><div>Neuroimmunology, a field exploring the intricate interplay between the nervous and immune systems, has long focused on the regulatory effects of stress on immune function. Chronic stress activates the hypothalamic-pituitary-adrenal axis and the sympathetic-adrenal-medullary system, leading to glucocorticoid and catecholamine release, which modulate T cell activity. Clinical studies reveal that chronic stress dysregulates peripheral T cells, particularly reducing CD4⁺ T cell counts, which are implicated in anxiety and obsessive-compulsive disorders. The current research demonstrates that chronic stress depletes peripheral CD4⁺ T cells, and their depletion protects against stress-induced anxiety-like behaviors. Furthermore, adoptive transfer of CD4⁺ T cells from anxious mice induces anxiety in recipient mice, highlighting the pivotal role of these cells in stress-related disorders. This finding uncovers a novel mechanism where stress triggers purine metabolism dysregulation in CD4⁺ T cells, leading to elevated xanthine and adenine levels. Xanthine enhances amygdala neuronal activity, contributing to anxiety-like behaviors, while adenine suppresses it. Stress-induced leukotriene B4 promotes mitochondrial fission in CD4⁺ T cells, enhancing IRF1 nuclear accumulation and upregulating purine synthesis enzymes, resulting in xanthine overproduction. This metabolic shift links mitochondrial dysfunction to stress-induced anxiety. Purines exert their effects via adenosine receptors, with A1 in oligodendrocytes mediating xanthine-induced neuronal activation in the brain. In the gut, stress-induced xanthine elevation activates A2B receptors, driving exosome biogenesis and contributing to irritable bowel syndrome pathogenesis. These findings identify dysregulated purine metabolism in CD4⁺ T cells as a hallmark of stress-related disorders, offering novel therapeutic targets. Purine synthesis inhibitors and adenosine receptor antagonists show promise in alleviating anxiety and IBS symptoms, paving the way for innovative treatments for stress-induced diseases. This research bridges neuroimmunology and metabolism, providing a comprehensive understanding of stress-related disorders and their therapeutic potential.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of chronic abdominal pain caused by non digestive or psychological disorders","authors":"Jianchang Wei,&nbsp;Yonglong Bao,&nbsp;Ping Yang,&nbsp;Shanqi Zeng,&nbsp;Jie Cao,&nbsp;Tong Zhang","doi":"10.1016/j.bbii.2025.100114","DOIUrl":"10.1016/j.bbii.2025.100114","url":null,"abstract":"<div><h3>Background</h3><div>Chronic abdominal pain (CAP) is defined as ongoing or recurring abdominal pain that lasts for three months or longer, presenting a complex medical challenge due to its wide range of possible causes. Here, we report a case of CAP caused by a non-digestive and non-psychological disorder.</div></div><div><h3>Case presentation</h3><div>A 49-year-old man began experiencing intermittent upper abdominal pain three months ago. Gastroenteroscopy revealed chronic non-atrophic gastritis with erosion and multiple colon polyps. He received treatment including proton pump inhibitors (PPIs), Chinese medicine, painkillers, and psychological therapy, but his symptoms did not improve. One day ago, his abdominal pain worsened along with fever of 38.5 °C. Computed tomography (CT) scan showed a foreign body (FB) and pneumoperitoneum. Urgent laparoscopic exploration was performed, revealing a 3.5 cm fishbone penetrating the left lobe of the liver. The fishbone was successfully removed, and his abdominal pain finally disappeared.</div></div><div><h3>Conclusion</h3><div>CAP is a complex condition with significant diagnostic challenges. Hepatic foreign bodies are very rare and are frequently overlooked in gastroenteroscopic evaluations, which can lead to delayed diagnoses. CT scanning is a crucial diagnostic tool for identifying FBs. Laparoscopic minimally invasive extraction is a viable option for FB removal when indicated. This case underscores the necessity of addressing both physical and psychological factors when managing CAP.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}